---
schema_version: "secwatch.filing_event.v1"
accession: "0001600620-25-000009"
form_type: "8-K"
ticker: "AUPH"
cik: "0001600620"
company_name: "Aurinia Pharmaceuticals Inc."
filed_at: "2025-02-27T23:59:59+00:00"
generated_at: "2026-05-26T01:51:25.343564+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Aurinia Q4 2024 net income $1.4M on 33% revenue growth, LUPKYNIS sales up 36% YoY

## Summary
- Q4 total revenue $59.9M (+33% YoY); net product sales $57.6M (+36%); license revenue $2.3M (-18%).
- Q4 net income $1.4M vs $(26.9)M loss; full year net income $5.8M vs $(78.0)M loss.
- Cash flow from operations Q4 $30.1M (+110% YoY); full year $44.4M vs $(33.5)M.
- 2025 guidance: total revenue $250-260M, net product sales $240-250M; AUR200 Phase 1 data expected Q2 2025.
- Cash $358.5M at Dec 31, 2024; repurchased 6.1M shares for $41M in 2024.

## SEC filing metadata
- accession: 0001600620-25-000009
- form_type: 8-K
- ticker: AUPH
- cik: 0001600620
- company_name: Aurinia Pharmaceuticals Inc.
- filed_at: 2025-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000009/0001600620-25-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1600620/000160062025000009/auph-20250227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001600620-25-000009
- JSON: https://secwatch.observer/filing/0001600620-25-000009.json
- Plain text: https://secwatch.observer/filing/0001600620-25-000009.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.